Jens Wagenblast
Goethe University Frankfurt
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jens Wagenblast.
British Journal of Cancer | 2014
Panagiotis Balermpas; Yvonne Michel; Jens Wagenblast; Oliver Seitz; Christian Weiss; Franz Rödel; Claus Rödel; Emmanouil Fokas
Background:We aimed to investigate the prognostic value of tumour-infiltrating lymphocytes’ (TILs) expression in pretreatment specimens from patients with head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiotherapy (CRT).Methods:The prevalence of CD3+, CD8+, CD4+ and FOXP3+ TILs was assessed using immunohistochemistry in tumour tissue obtained from 101 patients before CRT and was correlated with clinicopathological characteristics as well as local failure-free- (LFFS), distant metastases free- (DMFS), progression-free (PFS) and overall survival (OS). Survival curves were measured using the Kaplan–Meier method, and differences in survival between the groups were estimated using the log-rank test. Prognostic effects of TIL subset density were determined using the Cox regression analysis.Results:With a mean follow-up of 25 months (range, 2.3–63 months), OS at 2 years was 57.4% for the entire cohort. Patients with high immunohistochemical CD3 and CD8 expression had significantly increased OS (P=0.024 and P=0.028), PFS (P=0.044 and P=0.047) and DMFS (P=0.021 and P=0.026) but not LFFS (P=0.90 and P=0.104) in multivariate analysis that included predictive clinicopathologic factors, such as age, sex, T-stage, N-stage, tumour grading and localisation. Neither CD4 nor FOXP3 expression showed significance for the clinical outcome. The lower N-stage was associated with improved OS in the multivariate analysis (P=0.049).Conclusion:The positive correlation between a high number of infiltrating CD3+ and CD8+ cells and clinical outcome indicates that TILs may have a beneficial role in HNSCC patients and may serve as a biomarker to identify patients likely to benefit from definitive CRT.
Acta Oto-laryngologica | 2009
Wolfgang Gstoettner; Silke Helbig; Claudia Settevendemie; Uwe Baumann; Jens Wagenblast; Christoph Arnoldner
Conclusion. A so far unattained high rate (100%) of residual hearing preservation in cochlear implantation for electric-acoustic stimulation could be achieved using sophisticated surgical techniques in combination with the MedEl Flex EAS electrode. Objectives. This study aimed to gather first audiological and surgical results from the experience gained with the new MedEl Flex EAS electrode array. Patients and methods. Nine patients (aged 7.62–71.32 years) with profound high frequency hearing loss were supplied with this atraumatic electrode, which was designed to preserve residual hearing despite intracochlear insertion of an electrode array. All patients were implanted by the same surgeon. Results. Hearing preservation was achieved in all patients (complete preservation 44.44%) after a mean follow-up period of 9.73 months. Mean monosyllabic test scores improved from 9% correct with the hearing aid alone to 48% with the cochlear implant and to 65% in the electric-acoustic mode.
Physics in Medicine and Biology | 2007
Sotirios Bisdas; George N. Konstantinou; Puor Sherng Lee; Choon Hua Thng; Jens Wagenblast; Mehran Baghi; Tong San Koh
The objective of this work was to evaluate the feasibility of a two-compartment distributed-parameter (DP) tracer kinetic model to generate functional images of several physiologic parameters from dynamic contrast-enhanced CT data obtained of patients with extracranial head and neck tumors and to compare the DP functional images to those obtained by deconvolution-based DCE-CT data analysis. We performed post-processing of DCE-CT studies, obtained from 15 patients with benign and malignant head and neck cancer. We introduced a DP model of the impulse residue function for a capillary-tissue exchange unit, which accounts for the processes of convective transport and capillary-tissue exchange. The calculated parametric maps represented blood flow (F), intravascular blood volume (v(1)), extravascular extracellular blood volume (v(2)), vascular transit time (t(1)), permeability-surface area product (PS), transfer ratios k(12) and k(21), and the fraction of extracted tracer (E). Based on the same regions of interest (ROI) analysis, we calculated the tumor blood flow (BF), blood volume (BV) and mean transit time (MTT) by using a modified deconvolution-based analysis taking into account the extravasation of the contrast agent for PS imaging. We compared the corresponding values by using Bland-Altman plot analysis. We outlined 73 ROIs including tumor sites, lymph nodes and normal tissue. The Bland-Altman plot analysis revealed that the two methods showed an accepted degree of agreement for blood flow, and, thus, can be used interchangeably for measuring this parameter. Slightly worse agreement was observed between v(1) in the DP model and BV but even here the two tracer kinetic analyses can be used interchangeably. Under consideration of whether both techniques may be used interchangeably was the case of t(1) and MTT, as well as for measurements of the PS values. The application of the proposed DP model is feasible in the clinical routine and it can be used interchangeably for measuring blood flow and vascular volume with the commercially available reference standard of the deconvolution-based approach. The lack of substantial agreement between the measurements of vascular transit time and permeability-surface area product may be attributed to the different tracer kinetic principles employed by both models and the detailed capillary tissue exchange physiological modeling of the DP technique.
Laryngoscope | 2007
Mehran Baghi; Jens Wagenblast; Markus Hambek; Andreas Radeloff; Wolfgang Gstoettner; Agmal Scherzed; Birgit Spaenkuch; Juping Yuan; Stefan Hornung; Klaus Strebhardt; Rainald Knecht
Background: Relatives of cancer patients experience high levels of stress that influence the quality of life of these individuals. To investigate whether there is a necessity for simultaneous supportive care of patient relatives, we performed for the first time a study asking the closest relatives of head and neck cancer patients about their needs during and after the treatment to consider how to optimize the situation for such patient groups.
British Journal of Cancer | 2014
Panagiotis Balermpas; Franz Rödel; R Liberz; J Oppermann; Jens Wagenblast; S Ghanaati; P N Harter; M Mittelbronn; Christian Weiss; Claus Rödel; Emmanouil Fokas
Background:We investigated the prognostic role of tumour-associated macrophages (TAMs) in patients with head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiotherapy (CRT).Methods:The expression of CD68+, CD163+ and CD11b+ cells was assessed using immunohistochemistry in n=106 pre-treatment tumour biopsy samples and was correlated with clinicopathological characteristics, including T-stage, N-stage, grading, tumour localisation, age and sex as well as local failure-free survival (LFFS), distant metastases-free survival (DMFS), progression-free (PFS), and overall survival (OS). Finally, TAMs expression and vessel density (CD31) were examined in n=12 available early local recurrence samples and compared with their matched primary tumours . The diagnostic images and radiotherapy plans of these 12 patients were also analysed. All local recurrences occurred in the high radiation dose region (⩾70 Gy).Results:With a median follow-up of 40 months, OS at 2 years was 60.5%. High CD163 expression in primary tumours was associated with decreased OS (P=0.010), PFS (P=0.033), LFFS (P=0.036) and DMFS (P=0.038) in multivariate analysis. CD163 demonstrated a strong prognostic value only in human papillomavirus (p16INK4)-negative patients. Early local recurrence specimens demonstrated a significantly increased infiltration of CD11b+ myeloid cells (P=0.0097) but decreased CD31-positive vessel density (P=0.0004) compared with their matched primary samples.Conclusions:Altogether, baseline CD163 expression predicts for an unfavourable clinical outcome in HNSCC after definitive CRT. Early local recurrences showed increased infiltration by CD11b+ cells. These data provide important insight on the role of TAMs in mediating response to CRT in patients with HNSCC.
Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2007
Mehran Baghi; Martin G. Mack; Markus Hambek; Sotirios Bisdas; Ramona Muerthel; Jens Wagenblast; Wolfgang Gstoettner; Thomas J. Vogl; Rainald Knecht
The purpose was to evaluate the efficacy of tumor volumetry on MRI as predictive of response to treatment with induction chemotherapy, comparing the results with endoscopy.
Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2007
Markus Hambek; Mehran Baghi; Jens Wagenblast; Johannes Schmitt; Helena Baumann; Rainald Knecht
Prostaglandin E2 (PGE2) serum levels have been shown previously to be increased in tumor bearing mice as well as in patients with solid tumors; however, the impact on the course or stage of disease has not been shown. We hypothesized that PGE2 is strictly required for aggressive and especially early‐stage tumors of the head and neck to provoke invasion and angiogenesis.
International Journal of Radiation Oncology Biology Physics | 2012
Panagiotis Balermpas; Christian Keller; Markus Hambek; Jens Wagenblast; Oliver Seitz; Claus Rödel; Christian Weiss
PURPOSE To report our experience with a prospective protocol of external beam reirradiation (Re-RT) combined with cetuximab for patients with inoperable, recurrent squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS Between August 2008 and June 2010, 18 patients with inoperable recurrence of SCCHN after adjuvant or definitive radiotherapy (RT) and simultaneous or sequential cisplatin-based chemotherapy for primary SCCHN were enrolled. Acute and late toxicity from the experimental regimen were recorded every week during RT and every 3 months thereafter. Efficacy was assessed with repeated imaging using response evaluation criteria in solid tumors and clinical examinations 8-12 weeks after completion of the treatment and every 3 months thereafter. RESULTS Median follow-up time for all patients was 9.4 (range: 3.85-31.7) months and for patients alive 30.4 (range: 15.7-31.7) months. Acute toxicity was generally mild or moderate. Five patients developed a grade 3 acneiform rash related to cetuximab. Late toxicity occurred as grade 3 trismus in five and as grade 3 abacterial salivary gland inflammation in one patient, respectively. Overall response rate was 47%. Median overall and progression-free survival for all patients was 8.38 months and 7.33 months, respectively. The overall survival rate was 44% at 1 year, with a 1 year local control rate of 33%. CONCLUSION Notwithstanding the limitations of our preliminary data Re-RT combined with cetuximab for recurrent and inoperable SCCHN is feasible and the integration of newer targeted agents seems to be less toxic compared to conventional chemotherapy with encouraging response rates at least for a subset of patients.
Audiology and Neuro-otology | 2014
Clemens Honeder; Elisabeth Engleder; Hanna Schöpper; Franz Gabor; Gottfried Reznicek; Jens Wagenblast; Wolfgang Gstoettner; Christoph Arnoldner
The pharmacokinetic properties and tolerability of a triamcinolone acetonide poloxamer 407 hydrogel for intratympanic application were investigated in a guinea pig model. Evaluation of in vivo release kinetics showed very high initial perilymph drug levels, with clinically relevant levels present for a minimum of 10 days. Assessment of auditory brainstem response thresholds showed a minimal, delayed and transient threshold shift, which was apparent on day 3 and resolved by day 10. No relevant histological changes of the middle and inner ear structures were noted, and hair cell counts showed no significant differences between treated and untreated ears. Thus, the triamcinolone-acetonide-loaded poloxamer 407 hydrogel is an effective vehicle for sustained high-dose inner ear glucocorticoid delivery.
Advances in oto-rhino-laryngology | 2010
Christoph Arnoldner; Silke Helbig; Jens Wagenblast; Wolf-Dieter Baumgartner; Jafar-Sasan Hamzavi; Dominik Riss; Wolfgang Gstoettner
BACKGROUND/AIMS The aim of this study was to describe audiological outcomes and surgical considerations in electric acoustic stimulation for patients with severe to profound high-frequency hearing loss. METHODS In this latest series of patients in our center, all patients were supplied with the new (atraumatic) Flex EAS MED-EL electrode. Eleven patients (age 7.62-71.32 years) with profound high-frequency hearing loss were implanted with this electrode, which was designed to preserve residual hearing despite the intracochlear insertion of an electrode array. All patients were operated on by the same surgeon (W.G.). RESULTS The rate of complete or partial hearing preservation was 100% after a mean follow-up period of 7.85 months (range 0.95-15.65 months). CONCLUSION This study proves that both refined surgical techniques and atraumatic electrodes are mandatory to preserve residual hearing after cochlear implantation. Flexible, thin, and free-fitting straight electrodes, such as the MED-EL Flex EAS electrode used in this study, seem to most accurately meet the requirements for hearing preservation in electric acoustic stimulation.